“While the weight loss results were impressive across the group, the cost and side effects remain important barriers for long ...

Mounjaro (Tirzepatide), a groundbreaking GLP-1 receptor agonist targeting GIP receptors, is now available in India for ...

Mounjaro (tirzepatide) is an FDA-approved antidiabetic injection gaining popularity for its effectiveness in weight ...

Congress authorized the FDA to determine whether a drug is “in shortage in the United States.” The FDA’s determination of a drug shortage ...

Resmetirom offers a targeted approach to metabolic dysfunction–associated steatohepatitis (MASH) for use alongside lifestyle ...

Tirzepatide combined with lifestyle modification reduced the highest number of obesity cases (45,609 per 100,000 eligible individuals), diabetes cases (20,854 per 100,000 eligible individuals ...

Mounjaro and Trulicity are two injectable medications that treat type 2 diabetes. Learn more about their key similarities, ...

A recent study published in Diabetes Technology & Therapeutics has demonstrated that off-label use of semaglutide and tirzepatide leads to significant reductions in glycated haemoglobin (HbA1c ...

Semaglutide and tirzepatide were the least cost-effective of four obesity drugs examined in a microsimulation model. A multifaceted approach is needed to reduce financial barriers to obesity ...

Eli Lilly launches Mounjaro, the much-awaited diabetes drug, in India. It is priced at ₹3,500 for 2.5 mg. Mounjaro and ...

Adults with type 1 diabetes had greater declines in HbA1c and body weight 1 year after being prescribed semaglutide or tirzepatide. Randomized controlled trials are needed to assess efficacy and ...